MS Pharma Group, a Jordan-based pharmaceutical company, announced on Monday that it has entered into a strategic partnership with Hetero Group, a manufacturer of Active Pharmaceutical Ingredients (APIs) and generic formulations based in India.

This exclusive agreement will be implemented through El Kendi, MS Pharma Group's affiliate in Algeria, and Hetero Biopharma, a subsidiary of Hetero Group.

The collaboration is aimed at localising five established biosimilars across key therapeutic areas, including oncology, immunology and haematology. It marks Hetero's first local partnership in Algeria, representing a significant step towards strengthening the country's biopharmaceutical ecosystem.

The combined portfolio represents an estimated total market value of USD45m in Algeria (2024) and will be executed through a localisation and technology transfer approach.